Premium
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature
Author(s) -
Galluzzo Marco,
D'Adamio Simone,
Teoli Miriam,
Bianchi Luca,
Talamonti Marina
Publication year - 2019
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12899
Subject(s) - secukinumab , medicine , dermatology , acrodermatitis , refractory (planetary science) , psoriasis , generalized pustular psoriasis , psoriatic arthritis , pathology , physics , alternative medicine , astrobiology
Acrodermatitis continua of Hallopeau (ACH) is a rare pustular psoriasis variant refractory to many conventional treatments. We report the successful treatment with secukinumab of a patient with a long history of ACH with marked onychodystrophy with frank pustulosis on the nail bed and with accompanying arthritis. Blockade of the IL‐17 receptor A has shown promise in the treatment of psoriatic erythroderma and generalized pustular psoriasis not responsive to conventional treatment. A rapid response was observed in our patient, in both skin lesions and arthritic symptoms, underlining the ability of secukinumab to improve symptoms beyond those of plaque psoriasis.